Diamond BioFund
35F, No. 66, Sec. 1, Zhongxiao W. Rd., Zhongzheng Dist., Taipei City, 100507, Taiwan
Overview
Diamond Biofund is a venture capital and private equity firm that invests in life sciences, biotechnology, and healthcare companies.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- EyeYon
Participated · Series C · Mar 2021
EyeYon Medical develops EndoArt®, a synthetic artificial endothelial layer designed to be attached to the posterior corneal surface to treat chronic corneal edema caused by endothelial dysfunction. The minimally invasive implant aims to replace dysfunctional endothelium, restore corneal homeostasis and reduce vision loss, offering a potentially safer and simpler alternative to corneal transplantation. The company also markets an FDA‑approved therapeutic contact lens, Hyper CL™, for various corneal pathologies. EyeYon says additional funding will accelerate pivotal clinical studies and support regulatory clearances across multiple regions. The company has generated first‑in‑human clinical evidence validating EndoArt® safety and is now pursuing expanded trials. Recent financing is intended to advance EndoArt® clinical trials in the USA, China and Europe and to broaden surgeon access to the therapy. EyeYon Medical is an Israeli medtech company founded in 2011 at the VLX Technological Incubator by ophthalmologists. The company is developing a silicone disc implanted in place of the corneal endothelium as a synthetic substitute for corneal transplants. The new capital will be used to finance human clinical trials for that implant. EyeYon also markets Hyper-CL, a contact lens that has received FDA and CE certification and is being sold in Spain, Poland, India, and the US. The company has raised a total of $10 million to date. Nahum Ferera serves as CEO.
- Ativa Medical
Participated · Series B · Sep 2015
Ativa Medical is a St. Paul, Minn.-based growth medical diagnostic company developing and commercializing novel point-of-care diagnostic technologies. Led by James McNally, Ph.D., the company is pursuing approval and commercialization of an innovative tabletop Ativa micro lab. The micro lab is designed to enable health care professionals to perform critical hematology and blood chemistry tests on-site and obtain accurate results in five minutes. Ativa intends to use recent funding to advance product development and secure regulatory approval. The company raised $15M in Series B equity financing to support FDA approval efforts and preparations for commercial launch.
Team
No current team members are available.